



Onpattro® (patisiran) (Intravenous)

Last Review Date: October 1, 2019

Number: MG.MM.PH.119

Medical Guideline Disclaimer

C All rights reserved. The treating physician or primary care provider must submit to EmblemHealth the clinical evidence that the patient meets the criteria for the treatment or surgical procedure. Without this documentation and information, EmblemHealth will not be able to properly review the request for prior authorization. The clinical review criteria expressed below reflects how EmblemHealth determines whether certain services or supplies are medically necessary. EmblemHealth established the clinical review criteria based upon a review of currently available clinical information (including clinical outcome studies in the peer-reviewed published medical literature, regulatory status of the technology, evidence-based guidelines of public health and health research agencies, evidence-based guidelines and positions of leading national health professional organizations, views of physicians practicing in relevant clinical areas, and other relevant factors). EmblemHealth expressly reserves the right to revise these conclusions as clinical information changes, and welcomes further relevant information. Each benefit program defines which services are covered. The conclusion that a particular service or supply is medically necessary does not constitute a representation or warranty that this service or supply is covered and/or paid for by EmblemHealth, as some programs exclude coverage for services or supplies that EmblemHealth considers medically necessary. If there is a discrepancy between this guideline and a member's benefits program, the benefits program will govern. In addition, coverage may be mandated by applicable legal requirements of a state, the Federal Government or the Centers for Medicare & Medicaid Services (CMS) for Medicare and Medicaid members. All coding and web site links are accurate at time of publication. EmblemHealth Services Company LLC, ("EmblemHealth") has adopted the herein policy in providing management, administrative and other services to HIP Health Plan of New York, HIP Insurance Company of New York, Group Health Incorporated and GHI HMO Select, related to health benefit plans offered by these entities. All of the aforementioned entities are affiliated companies under common control of EmblemHealth Inc.

Definition

Patisiran was FDA approved for the treatment of the polyneuropathy of hATTR amyloidosis in adults. hATTR amyloidosis is a rapidly progressive, life-threatening disease caused by mutant and wild-type transthyretin (TTR) proteins forming amyloid deposits in tissues throughout the body. More than 95% of TTR circulating in the body is produced by the liver. This amyloid accumulation leads to progressive multisystem dysfunction, including polyneuropathy (e.g., sensorimotor and autonomic neuropathy) and cardiomyopathy. Patisiran is a double-stranded small interfering ribonucleic acid (siRNA) formulated as a lipid nanoparticle complex for delivery to hepatocytes. Patisiran causes the degradation of mutant and wild-type TTR mRNA through RNA interference, which results in a reduction of serum TTR protein and TTR protein deposits in tissues.

Length of Authorization

Coverage will be provided for 6 months and may be renewed.

Dosing Limits

Max Units (per dose and over time) [Medical Benefit]:

- 30 mg every 3 weeks

Guideline

I. INITIAL APPROVAL CRITERIA

Patisiran may be considered medically necessary if one of the below conditions are met **AND** use is consistent with the medical necessity criteria that follows:

Polyneuropathy of hATTR amyloidosis†

- Patient must be at least 18 years old; **AND**

- Patient has a definitive diagnosis of hATTR amyloidosis/FAP as documented by identification of a pathogenic TTR variant using molecular genetic testing; **AND**
- Used for the treatment of polyneuropathy as demonstrated by at least TWO of the following criteria:
 - Subjective patient symptoms are suggestive of neuropathy
 - Abnormal nerve conduction studies are consistent with polyneuropathy
 - Abnormal neurological examination is suggestive of neuropathy; **AND**
- Patient’s peripheral neuropathy is attributed to hATTR/FAP and other causes of neuropathy have been excluded; **AND**
- Baseline in strength/weakness has been documented using an objective clinical measuring tool (e.g., Medical Research Council (MRC) muscle strength, etc.); **AND**
- Patient has not been the recipient of an orthotopic liver transplant (OLT); **AND**
- Patient is receiving supplementation with vitamin A at the recommended daily allowance

† FDA-labeled indication(s);

Limitations/Exclusions

Onpattro is not considered medically necessary for indications other than those listed above due to insufficient evidence of therapeutic value.

II. RENEWAL CRITERIA

- Patient continues to meet Initial approval criteria.
- Disease response compared to baseline prior to treatment shows improvement or stabilization in one or both of the following:
 - Neuropathy signs and symptoms
 - MRC muscle strength

Dosage/Administration

Indication	Dose
hATTR Amloidosis	<p>Recommended dosage:</p> <ul style="list-style-type: none"> • Weight < 100 kg <ul style="list-style-type: none"> ○ 0.3 mg/kg intravenously every 3 weeks • Weight ≥ 100 kg <ul style="list-style-type: none"> ○ 30 mg intravenously every 3 weeks <p>Preparing for Therapy:</p> <ul style="list-style-type: none"> • Dosing is based on actual body weight • Patients should be premedicated with a corticosteroid, acetaminophen and antihistamines. • Infusion should be filtered and diluted and infused, via a pump, over at least 80 minutes. • Patients should receive vitamin A supplementation.

Applicable Procedure Codes

C9036	Injection, patisiran, 0.1mg
J0222	Effective 10/1/19, Injection, patisiran, 0.1mg

Applicable NDCs

71336-1000-01	Onpattro 10mg/5ml single-dose vial
---------------	------------------------------------

Applicable Diagnosis Codes

ICD-10	ICD-10 Description
E85.1	Neuropathic heredofamilial amyloidosis

Revision History

8/15/2019	Added code J0222, effective 10/1/19
-----------	-------------------------------------

References

1. ONPATTRO (patisiran) [package insert]. Cambridge, MA: Alnylam Pharmaceuticals, Inc; 2018.
2. Adams D, González-Duarte A, O’Riordan WD, et al. Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. *N Engl J Med.* 2018;379(1):11-21.
3. Adams D, Suhr OB, Dyck PJ, et al. Trial design and rationale for APOLLO, a Phase 3, placebo-controlled study of patisiran in patients with hereditary ATTR amyloidosis with polyneuropathy. *BMC Neurol.* 2017;17(1):181